Vleminckx (Vleminckx, Vinas / Tensoderm Scrub / Tensoderm)

Author Correction: RSPO2 inhibition of RNF43 and ZNRF3 governs limb development independently of LGR4/5/6.

Szenker-Ravi Emmanuelle E, Altunoglu Umut U, Leushacke Marc M, Bosso-Lefèvre Célia C et al.

In this Letter, the surname of author Lena Vlaminck was misspelled 'Vlaeminck'. In addition, author Kris Vleminckx should have been associated with affiliation 16 (Center for Medical Genetics, Ghent University, Ghent, Belgium). These have been corrected online.

Pyoderma faciale: a clinical study of twenty-nine patients.

Massa M C MC, Su W P WP

Pyoderma faciale is a distinctive entity. Twenty-nine patients with this process were seen in the Mayo Clinic from 1969 to 1980. Twenty-seven patients had follow-up that ranged from 1 month to 11 years, and twenty-two had follow-up of 3 years or more. Clinical features that characterize the patients were (1) female predominance, (2) onset later than teenage acne vulgaris, generally at 19 to 40 years of age, (3) rapid onset and progression, (4) facial involvement with sparing of the back and chest, (5) cysts, swelling, and purulent drainage with a lack of comedones, and (6) paucity of systemic complaints. Patients were treated with multiple forms of therapy simultaneously, often including Vleminckx packs, oral antibiotics, incision and drainage, ultraviolet B, and intralesional steroids. Of twenty-five patients available for follow-up at 1 year, twenty-three had achieved remission, though fifteen patients required ongoing treatment to maintain optimal control. Twenty-three patients had scarring as a sequela. Patients with pyoderma faciale represent a subset of patients with acne in whom the outlook is favorable with appropriate therapy.

Topical deodorized polysulfides. Broadscope acne therapy.

Elstein W W

True Vleminckx's solution incorporated in a natural clay-mask vehicle apparently retains its therapeutic qualities while relinquishing all unaesthetic properties. A double-blind, randomized clinical trial comparing the Vleminckx mask to its vehicle was conducted. While the mask vehicle may not be considered a placebo, only the active drug produced a statistically significant reduction in comedone count at the conclusion of the study. The Vleminckx mask achieved a substantially greater reduction in papule count than the vehicle (p less than 0.05). Male and female patients responded positively to the concept of every-other-evening applications of only 20 minutes, as well as to the mask's rapidly astringent and cooling skin effects.

Vleminckx solution for resistant plantar excrescences.

THOMPSON L B LB